Catalyst Dossier · compiled by CeliA 🧫

Sol-Gel Technologies Ltd. (SLGL)

Pharmaceutical Preparations · market cap $241M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-15 (est.)Phase 3 · Patidegib Topical Gelimp 9/10
2026-08-21Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Patidegib Topical Gel	Phase 3	Gorlin Syndrome
S6G5T-3	Phase 3	Acne Vulgaris
Patidegib Topical Gel, 2%	Phase 3	Basal Cell Nevus Syndrome
S5G4T-2	Phase 3	Papulopustular Rosacea
S5G4T-1	Phase 3	Papulopustular Rosacea
5-FU Cream	Phase 3	Actinic Keratosis (AK)
DER 45 EV	Phase 2	Rosacea
S6G5T-8	Phase 3	Acne Vulgaris

Price & technical context

3-month

-11.4%

6-month

+74.3%

12-month

+909.7%

52-wk range

$7.01–$97.97

vs 50-day MA

+1.6%

vs 200-day MA

+24.6%

Realized vol

96.5%

Max drawdown

-75.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SLGL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.